>
Switch to:

Opiant Pharmaceuticals Revenue per Share

: $7.78 (TTM As of Jun. 2021)
View and export this data going back to 2007. Start your Free Trial

Opiant Pharmaceuticals's revenue per share for the three months ended in Jun. 2021 was $2.07. Opiant Pharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Jun. 2021 was $7.78.

Warning Sign:

Opiant Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Opiant Pharmaceuticals was 0.80% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -5.50% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 37.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Opiant Pharmaceuticals's Revenue per Share or its related term are showing as below:

NAS:OPNT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.5   Med: 13.5   Max: 76.3
Current: -5.5

-5.5
76.3

During the past 13 years, Opiant Pharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 76.30% per year. The lowest was -5.50% per year. And the median was 13.50% per year.

NAS:OPNT's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 190 Companies
in the Biotechnology industry.

( Industry Median: -14.95 vs. NAS:OPNT: -5.50 )

Opiant Pharmaceuticals Revenue per Share Historical Data

The historical data trend for Opiant Pharmaceuticals's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20
Revenue per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.18 8.25 4.68 7.59 6.97

Opiant Pharmaceuticals Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Revenue per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 1.88 2.33 1.49 2.07

Opiant Pharmaceuticals Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Opiant Pharmaceuticals's Revenue Per Share for the fiscal year that ended in Dec. 2020 is calculated as

Revenue Per Share (A: Dec. 2020 )=Revenue (A: Dec. 2020 )/Shares Outstanding (Diluted Average) (A: Dec. 2020 )
=29.625/4.250
=6.97

Opiant Pharmaceuticals's Revenue Per Share for the quarter that ended in Jun. 2021 is calculated as

Revenue Per Share (Q: Jun. 2021 )=Revenue (Q: Jun. 2021 )/Shares Outstanding (Diluted Average) (Q: Jun. 2021 )
=11.259/5.428
=2.07

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opiant Pharmaceuticals  (NAS:OPNT) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Opiant Pharmaceuticals Revenue per Share Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals Business Description

Opiant Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
233 Wilshire Blvd, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
Thomas Thomas T. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Sinclair Michael director, 10 percent owner 86 GLOUCESTER PLACE LONDON XX W1U6HP
Collard Craig A director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Daly Richard J director 355 ALHAMBRA CIRCLE SUITE 1500 CORAL GABLES FL 33134
Macdougall Ann L. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Silver Gabrielle Alison director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Gorman Brian other: General Counsel 233 WILSHIRE BLVD SUITE 280 SANTA MONICA CA 90401
Skolnick Phil officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC. 433 HACKENSACK AVENUE HACKENSACK NJ 07601
Crystal Roger director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE 10TH FL. NEW YORK NY 10022
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC. 201 SANTA MONICA BLVD., SUITE 500 SANTA MONICA CA 90401
Thompson Rahsaan other: General Counsel 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Mottiwala Aziz officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Wolf Geoffrey 10 percent owner 445 PARK AVENUE 10TH FL. NEW YORK NY 10022
Pollack Kevin director, officer: See Remarks 150 RAINVILLE ROAD TARPON SPRINGS FL 34689
Meuse Joseph J director, 10 percent owner 211 FALMOUTH STREET WARRENTON VA 20186

Opiant Pharmaceuticals Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)